For decades, Alzheimer’s disease was treated as an unavoidable consequence of aging. In this episode of Research Renaissance, Dr. Jessica Rexach explains why that framing is no longer true.

Drawing on 20 years at the intersection of clinical neurology, genetics, and experimental neuroscience, Dr. Rexach walks us through a profound shift in the field. Today, scientists can model human brain circuits, measure Alzheimer’s pathology through blood-based biomarkers, and study why some brains remain cognitively resilient even with disease pathology present.

The science, she argues, is ready. The real question is whether society will commit the resources needed to finish the job.

Key Takeaways

• Alzheimer’s research has moved from broad hypotheses to precise, testable mechanisms
• Blood-based biomarkers have transformed clinical trials and early detection
• Brain resilience, not just pathology, may hold the key to prevention
• COVID-era investments unintentionally accelerated dementia research tools
• The biggest risk now is not scientific failure, but loss of funding and momentum

Guest Information

Dr. Jessica Rexach
Assistant Professor, UCLA
2024 Toffler Scholar

📧 Email: [email protected]

Listen & Subscribe

If you found this episode valuable:

• Subscribe to Research Renaissance on Apple Podcasts or Spotify
• Share this episode with colleagues, caregivers, or anyone interested in brain science
• Leave a review to help others discover the show

To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org.

Technical Podcast Support by Jon Keur at Wayfare Recording Co.